Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab in second-line malignant mesothelioma
NCT01655888Phase 2
Key facts
- Status
- Unknown
- Start
- Jul 2012
- Primary completion
- Jan 2014
- Countries
- 1
- Sponsor
- Azienda Ospedaliera Universitaria Senese
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Drugs
- tremelimumab
- Conditions
- malignant mesothelioma
01
Overview
Phase 2, open-label trial of tremelimumab in malignant mesothelioma, sponsored by Azienda Ospedaliera Universitaria Senese. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Registry description
RATIONAL: Preliminary results fron the Study MESOT-TREM-2012 indicate a promising activity of tremelimumab in malignant mesothelioma (MM) patients.
PURPOSE: The proposed study MESOT-TREM-2012 aims to explore the efficacy of a more intensive schedule of treatment with tremelimumab in 29 MM patients. Subjects will receive investigational product every 4 weeks (wks) for 6 doses, followed by doses every 12 wks until confirmed disease progression.
Beyond the preview
Go deeper on NCT01655888.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01655888.